Elevated serum levels of lysophosphatidic acid in patients with multiple sclerosis

Human Immunology

Volumn 75, Issue 5, 2014, Pages 411-413

  Balood, Mohammad ^a   Zahednasab, Hamid ^a   Siroos, Bahaaddin ^b   Mesbah Namin, Seyed Alireza ^a   Torbati, Sara ^b   Harirchian, Mohammad Hossein ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPID;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNE EVASION; MALE; MULTIPLE SCLEROSIS; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; T LYMPHOCYTE; YOUNG ADULT; BLOOD;

ADULT; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84896543726     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2014.02.021     Document Type: Article

References (18)

1. Ramagopalan S.V., Dobson R., Meier U.C., Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010, 9:727.
2. Hauser S.L., Oksenberg J.R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006, 52:61-76.
3. Frischer J.M., Bramow S., Dal-Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
4. Brück W., Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol Sci 2003, 24:s265-s267.
5. Shirani A., Zhao Y., Karim M.E., Evans C., Kingwell E., van der Kop M.L., et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012, 308:247-256.
6. Semra Y., Seidi O., Sharief M. Overexpression of the apoptosis inhibitor flip in T cells correlates with disease activity in multiple sclerosis. J Neuroimmunol 2001, 113:268-274.
7. Stracke M., Krutzsch H.C., Unsworth E.J., Arestad A., Cioce V., Schiffmann E., et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992, 267:2524-2529.
8. Goetzl E.J., An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J 1998, 12:1589-1598.
9. Moolenaar W.H. Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 1999, 253:230-238.
10. Tigyi G. Physiological responses to lysophosphatidic acid and related glycero-phospholipids. Prostaglandins Other Lipid Mediat 2001, 64:47-62.
11. Zhao Y., Natarajan V. Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling. Cell signalling 2009, 21:367-377.
12. Goetzl E.J., Kong Y., Mei B. Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of bax. J Immunol 1999, 162:2049-2056.
13. Tokumura A., Carbone L.D., Yoshioka Y., Morishige J., Kikuchi M., Postlethwaite A., et al. Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci 2009, 6:168.
14. Chun J., Rosen H. Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases. Curr Pharm Des 2006, 12:161-171.
15. Pelletier D., Hafler D.A. Fingolimod for multiple sclerosis. N Engl J Med 2012, 366:339-347.
16. Pitman M., Woodcock J., Lopez A., Pitson S. Molecular targets of FTY720 (fingolimod). Curr Mol Med 2012, 12:1207-1219.
17. Cyster J.G., Schwab S.R. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 2012, 30:69-94.
18. Hammack B.N.F.K., Hunsucker S.W., Duncan M.W., Burgoon M.P., Owens G.P., Gilden D.H. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler J 2004, 10:245-260.